These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 27387019)

  • 21. Changes of osteoprotegerin before and after insulin therapy in type 1 diabetic patients.
    Xiang GD; Sun HL; Zhao LS
    Diabetes Res Clin Pract; 2007 May; 76(2):199-206. PubMed ID: 17023086
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Circulating osteoprotegerin and asymptomatic carotid atherosclerosis in postmenopausal non diabetic women.
    Albu A; Bondor CI; Crăciun AM; Fodor D
    Adv Med Sci; 2014 Sep; 59(2):293-8. PubMed ID: 25240503
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Von Willebrand factor in relation to coronary plaque characteristics and cardiovascular outcome. Results of the ATHEROREMO-IVUS study.
    Sonneveld MA; Cheng JM; Oemrawsingh RM; de Maat MP; Kardys I; Garcia-Garcia HM; van Geuns RJ; Regar E; Serruys PW; Boersma E; Akkerhuis KM; Leebeek FW
    Thromb Haemost; 2015 Mar; 113(3):577-84. PubMed ID: 25472874
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of Endovascular Interventions on vWF and Fb Levels in Type 2 Diabetic Patients with Peripheral Artery Disease.
    Yao HQ; Wang FJ; Kang Z
    Ann Vasc Surg; 2016 May; 33():159-66. PubMed ID: 26902942
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization of tibial velocities by duplex ultrasound in severe peripheral arterial disease and controls.
    Crawford JD; Robbins NG; Harry LA; Wilson DG; McLafferty RB; Mitchell EL; Landry GJ; Moneta GL
    J Vasc Surg; 2016 Mar; 63(3):646-51. PubMed ID: 26620716
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization of the interaction between von Willebrand factor and osteoprotegerin.
    Shahbazi S; Lenting PJ; Fribourg C; Terraube V; Denis CV; Christophe OD
    J Thromb Haemost; 2007 Sep; 5(9):1956-62. PubMed ID: 17723135
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of percutaneous lower-extremity arterial interventions on endothelial function and inflammation response in patients with both type 2 diabetes and lower-extremity peripheral arterial disease.
    Du Y; Wang F; Qi H; Ding H; Hou L; Gao Q; Tan M; Liu Y; Xing N; Sun J
    Int J Clin Exp Pathol; 2015; 8(7):8115-21. PubMed ID: 26339379
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Changes in endothelial function and its association with plasma osteoprotegerin in hypothyroidism with exercise-induced silent myocardial ischaemia.
    Guang-da X; Hui-ling S; Jie H
    Clin Endocrinol (Oxf); 2008 Nov; 69(5):799-803. PubMed ID: 18410551
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Matrix metalloproteinase 10 is associated with disease severity and mortality in patients with peripheral arterial disease.
    Martinez-Aguilar E; Gomez-Rodriguez V; Orbe J; Rodriguez JA; Fernández-Alonso L; Roncal C; Páramo JA
    J Vasc Surg; 2015 Feb; 61(2):428-35. PubMed ID: 25441671
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The relationship between serum levels of vascular calcification inhibitors and carotid plaque vulnerability.
    Kadoglou NP; Gerasimidis T; Golemati S; Kapelouzou A; Karayannacos PE; Liapis CD
    J Vasc Surg; 2008 Jan; 47(1):55-62. PubMed ID: 18178454
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The value of serum osteoprotegerin levels in patients with angina like chest pain undergoing diagnostic coronary angiography.
    Ghaffari S; Yaghoubi A; Baghernejad R; Sepehrvand N; Sokhanvar S; Haghjou AG
    Cardiol J; 2013; 20(3):261-7. PubMed ID: 23788300
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of osteoprotegerin to traditional atherosclerotic risk factors and high-sensitivity C-reactive protein for diagnosis of atherosclerosis.
    Mogelvang R; Pedersen SH; Flyvbjerg A; Bjerre M; Iversen AZ; Galatius S; Frystyk J; Jensen JS
    Am J Cardiol; 2012 Feb; 109(4):515-20. PubMed ID: 22100028
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inverse regulation of serum osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand levels in patients with leg lesional vascular calcification: An observational study.
    Moon AR; Park Y; Chang JH; Lee SS
    Medicine (Baltimore); 2019 Mar; 98(10):e14489. PubMed ID: 30855435
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increased plasma osteoprotegerin levels are associated with the presence and severity of acute coronary syndrome.
    Ren MY; Sui SJ; Zhang Y; Xu FY; Xu XQ; Zhao JJ; Du YM; Liu WH
    Acta Cardiol; 2008 Oct; 63(5):615-22. PubMed ID: 19014006
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Changes in plasma concentrations of osteoprotegerin before and after levothyroxine replacement therapy in hypothyroid patients].
    Xiang GD; Sun HL; Zhao LS; Hou J; Yue L
    Zhonghua Yi Xue Za Zhi; 2007 Aug; 87(30):2121-5. PubMed ID: 17988532
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Microvascular dysfunction is associated with plasma osteoprotegerin levels in patients with acute myocardial infarction.
    Løgstrup BB; Høfsten DE; Christophersen TB; Møller JE; Bjerre M; Flyvbjerg A; Bøtker HE; Egstrup K
    Coron Artery Dis; 2013 Sep; 24(6):487-92. PubMed ID: 23777975
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum osteoprotegerin levels in patients with acute atherothrombotic stroke and lacunar infarct.
    Guldiken B; Guldiken S; Turgut B; Turgut N; Demir M; Celik Y; Arikan E; Tugrul A
    Thromb Res; 2007; 120(4):511-6. PubMed ID: 17258300
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Osteoprotegerin is associated with cardiovascular risk in hypertension and/or diabetes.
    Blázquez-Medela AM; García-Ortiz L; Gómez-Marcos MA; Recio-Rodriguez JI; Sánchez-Rodríguez A; López-Novoa JM; Martínez-Salgado C
    Eur J Clin Invest; 2012 May; 42(5):548-56. PubMed ID: 22050177
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of unfractionated heparin, enoxaparin and sulodexide on the relations between secretion and expression of OPG, RANKL and vWF in HUVEC.
    Lekesiz K; Naumnik B; Borysewicz-Sanczyk H; Koc-Zurawska E; Mysliwiec M
    Folia Histochem Cytobiol; 2013; 51(2):156-63. PubMed ID: 23907946
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Marked elevation in plasma osteoprotegerin constitutes an early and consistent feature of cerebral malaria.
    O'Regan N; Moxon C; Gegenbauer K; O'Sullivan JM; Chion A; Smith OP; Preston RJ; Brophy TM; Craig AG; O'Donnell JS
    Thromb Haemost; 2016 Apr; 115(4):773-80. PubMed ID: 26766771
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.